Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lenidase is a phytotherapy agent and dietary supplement formulated to manage inflammation and edema, particularly following surgical procedures such as third molar extraction. It contains a combination of three active components: bromelain, a proteolytic enzyme derived from pineapple that modulates inflammatory mediators; escin, a triterpene saponin from horse chestnut that reduces capillary permeability and improves vascular tone; and Vaccinium myrtillus (blueberry) extract, which provides antioxidant anthocyanins to protect microcirculation. Developed by Shedir Pharma, Lenidase is used to alleviate postoperative swelling and pain by targeting the underlying mechanisms of tissue congestion and inflammatory response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lenidase.